Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Coil treatment may offer brain bleed patients a Surgery-Free option

NCT ID NCT07197840

First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 27 times

Summary

This study tests a device called the Numen SILK coil, which is placed into the middle meningeal artery to block blood flow and help resolve chronic subdural hematoma—a slow brain bleed common in older adults. Researchers will enroll 100 people to see if this minimally invasive procedure reduces the need for rescue surgery or death within 180 days. The goal is to offer a less risky alternative to traditional brain surgery.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC SUBDURAL HEMORRHAGE (CSDH) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Icahn School of Medicine at Mount Sinai

    New York, New York, 10029, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Numen SILK coil embolization system (a device that blocks blood flow in the middle meningeal artery)

What this could lead to

If successful, this minimally invasive coil procedure could become a standard way to treat chronic subdural hematoma, reducing the need for brain surgery and lowering the chance of blood re-accumulation.

What could go wrong

This is a single-arm, post-market study with no comparison group, so results may be less definitive. The procedure carries risks such as bleeding, infection, or coil migration, and it may not work for all patients.

Conditions

The condition(s) this trial relates to.

Hematoma, Subdural, Chronic

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.